Merck’s Gardasil is a potent vaccine against HPV, a sexually transmitted disease that can cause cervical cancer. But until recently, cost and production constraints limited its reach. Merck has now committed more than $1 billion to expand capacity, with a focus on underserved countries. Merck more than doubled global supply of Gardasil between 2017 and 2020 and is on track to do so again by 2023.
Courtesy of Merck

Company Information

As of 4/4/23
Country
U.S.
Headquarters
Kenilworth, N.J.
Industry
Pharmaceuticals
CEO
Robert Davis
Company Type
Public
Ticker
MRK
Revenues ($M)
$59,283
Profits ($M)
$14,519
Market Value ($M)
$264,267
Employees
68,000
Figures are for fiscal year ended Dec. 31, 2022. Market value as of March 17, 2023. Sources: S&P Global; Bloomberg.

Change the World

Impact Segment
Public Health
Sector
Health Care
Prior Year Rank
-

Historical Data

YearRevenues ($M)Profits ($M)
2018$40,122$2,394
FortuneDataStore ad
Lists ranking Merck
RANK262
Global 500 - 2022Aggregate sales hit $37.8 trillion last year—an in...READ MORE
RANK100000
World's Most Admired Companies - 2023The 25th Fortune World’s Most Admired Companies li...READ MORE
RANK71
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MORE
RANK42
Change the World - 2022...READ MORE